

BETTER HEALTH PARTNERSHIPS

VACCINES



There are over **40 ACTIVE** partnerships for **VACCINES** around the world involving **SEVEN** innovative vaccine IFPMA member companies. The partnerships enable us to **EXPAND ACCESS TO LIFE-SAVING VACCINES**, working together towards an aspiration that **EVERY PERSON OF ANY AGE** who can be protected through immunization, is protected by vaccines.

IMPACT OF LIFE-COURSE IMMUNIZATION ON SOCIETY



MILLIONS OF LIVES SAVED AT ALL AGES




UNLOCK HEALTH & ECONOMIC BENEFITS



MOST EFFECTIVE PUBLIC HEALTH INVESTMENTS

FOR EACH \$1 SPENT ON CHILDHOOD IMMUNIZATION THE ESTIMATED RETURN FOR SOCIETY IS \$44

ACTIVE VACCINE PARTNERSHIPS BY DISEASE



NUMBER OF PARTNERSHIPS

EXAMPLE OF PARTNERSHIPS:



Vaccine Discovery Partnership

GlaxoSmithKline with the Bill and Melinda Gates Foundation facilitates research into vaccines for global health needs.



PATH Malaria Vaccine Initiative

With PATH and New York University, MSD develops a malaria vaccine on a novel protein sequence.



Humanitarian Emergency Settings

Pfizer enables broader access to its multi-dose vial at the lowest prevailing price and will donate proceeds from the program's first year to humanitarian groups.



Global Polio Eradication Initiative

Sanofi Pasteur is a long-standing partner of the Global Polio Eradication initiative, together with Unicef, WHO, Rotary International, and the Bill & Melinda Gates Foundation.




Myanmar Snakebite Project

Partnering with University of Adelaide in a 3 year project to save lives from venomous snake bites in South-East Myanmar



Measles Vaccination for Children

In partnership with the United Nations Foundation, Takeda will support immunizing 5.4 million children in Africa, Asia and Latin America.



TYPES OF PARTNERSHIPS



INNOVATION ACCESS



CAPACITY BUILDING TRAINING

TYPES OF PARTNERS



HEALTH CARE PROFESSIONALS GOVERNMENTS



NGOs ACADEMIA

SNAPSHOT OF IFPMA MEMBERSHIP VACCINE PARTNERSHIPS



Aeras' goal is to develop, test, characterize, license, manufacture and distribute at least one new TB vaccine within 10 years.



GAVI Alliance unites public and private sectors to create equal access to new and underused vaccines for children living in the world's poorest countries.



GHIT is a product development fund for global health research and development, including a vaccine development for malaria.



IAVI was created in 1996 and works with more than 50 partners to develop and assess candidate HIV vaccines.



Hilleman develops affordable vaccines in developing countries. It aims to strengthen public health systems and immunization programs.



The Coalition for Epidemic Preparedness Innovation (CEPI) accelerates research and development of vaccines for emerging infectious diseases.



IFPMA members provided WHO with nearly 90% of PIP funds & significantly contribute to securing pandemic doses for next pandemic.



CHECK OUT THE PARTNERSHIP DIRECTORY

Discover more about our global vaccines partnerships <http://partnerships.ifpma.org>

